ArticleBMC geriatrics2025
Challenging the age barrier: comparative outcomes in octogenarian and non-octogenarian colorectal cancer patients.
Article in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe treatment of colorectal cancer (CRC) in elderly patients, particularly in octogenarians, presents unique challenges due to comorbidities and presumed treatment intolerance. However, real-world data on outcomes in this age group remain limited.
objectiveThis study aims to evaluate and compare the clinical characteristics, treatment modalities, toxicities, and survival outcomes of octogenarian CRC patients with those of younger cohorts.
methodsIn this retrospective cohort study, 111 patients diagnosed with stage I-III CRC between March 2021 and December 2023 were analyzed. Patients were stratified into three age groups: octogenarians (≥ 80 years), non-octogenarian elderly (65-79 years), and non-elderly (< 65 years). Data on demographics, comorbidities, ECOG performance status, tumor features, treatment modalities, toxicities, and survival were collected. Survival outcomes were analyzed using Kaplan-Meier and log-rank tests.
resultsAmong the patients, 35.1% were octogenarians. Octogenarians had a significantly higher comorbidity burden but similar ECOG scores compared to younger groups. Combined local and systemic treatment was administered in 78.2% of octogenarians and was well tolerated, with comparable hematologic (15.4%) and non-hematologic (28.2%) toxicities across age groups. Disease-free survival (DFS) and overall survival (OS) were favorable in octogenarians, with 36-month OS reaching 91.8%, comparable to or slightly better than non-elderly patients (77.6%). These findings should be interpreted cautiously due to the limited sample size. The non-octogenarian elderly group demonstrated the highest survival rates overall.
conclusionOctogenarians with non-metastatic CRC can achieve favorable treatment outcomes comparable to or even better than younger patients, supporting the feasibility of curative-intent treatment in this age group. Age alone should not preclude standard oncologic management in elderly CRC patients. However, the single-center design and modest sample size limit generalizability, and further multicenter validation is required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.